Peripheral primitive neuroectodermal tumors (pPNETs) are small embryonic carcinomas that develop in the soft tissue and bone, away from the central nervous system (CNS) and sympathetic nervous system ...

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo. The Food and Drug Administration (FDA) has approved Cabometyx ® (cabozantinib) for ...

In addition to the some of the above studies being retrospective, the conflicting data between multiple studies seem to originate from two major issues, the first one being the stage of patients ...

Neuroendocrine Cancer UK (NCUK) says there is an urgent need to speed up the diagnosis of neuroendocrine cancer, which refers to a group of cancers that start in the nerve and gland cells that make ...

MIAMI, FLORIDA (April 30, 2024) – Newly updated guidelines on neuroendocrine tumors developed by an expert at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine ...

The US Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx, Exelixis, Inc.) for certain adults and children aged ≥ 12 years with previously treated, well-differentiated pancreatic ...

Incidence and diagnosis of neuroendocrine tumors (NETs) have risen significantly over the last several decades. According to research published in JAMA Network Open in 2025, the incidence of NETs ...

By 2030, the market is expected to reach $2.88 billion, driven by an increased focus on rare cancer treatments, advanced oncology care faciliti ...

Symptoms of neuroendocrine tumors (NETs) can vary depending on their location and severity. General symptoms include extreme fatigue, unexplained weight loss, and loss of appetite. NETs are a rare ...